Search Media Items

Signs and symptoms vary between acute, subacute, and chronic hypersensitivity pneumonitis and may include flu-like illness including fever, chills, muscle or joint pain, or headaches; rales; cough; chronic bronchitis; shortness of breath; anorexia or weight loss; fatigue; fibrosis of the lungs; or clubbing of fingers or toes. Complications of chronic disease may include irreversible lung damage, permanently reduced lung function, pulmonary hypotension, or heart failure.

There are no screening methods to determine who will or will not develop hypersensitivity pneumonitis and the only prevention is to avoid common environmental sources of substances known to cause this condition.

Risk factors for developing hypersensitivity pneumonitis include age, environment or occupation, family history and genetics, lifestyle habits, other medical conditions, and possibly sex or gender.

Hypersensitivity pneumonitis is caused by repeated exposure to environmental substances that cause inflammation in the lungs when inhaled. Substances include: bacteria, fungi or molds, proteins, or chemicals.

Public health news releases, CDC press releases, medical news, health news, CDC studies, news

Protect Babies from Whooping Cough Infographic

CDC works 24/7 to save lives, reduce disease, and improve health around the world.

Chickenpox and Varicella multimedia products including web features and podcasts.

Antibiotic resistance – when bacteria change and cause antibiotics to fail – is happening RIGHT NOW, across the world.

Childhood vascular tumor treatment depends on the specific type and location, can involve surgery, and may be followed by chemotherapy or radiation. Targeted therapy, immunotherapy, and other medications may be used. Learn more about vascular tumors in this expert-reviewed summary.

Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.

Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection.

In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.

The latest science-based information concerning some common misconceptions about cancer. Learn the facts to worry less and make good health decisions.

Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.